Explore
Featured
Recent
Articles
Topics
Login
Upload
Featured
Recent
Articles
Topics
Login
Upload
Search Results for 'treatment psa'
treatment psa published presentations and documents on DocSlides.
Updates for Dermatologists and Rheumatologists on PsA Management: Role of IL-17 Inhibitors
by marina-yarberry
IL-17 Inhibitors in the Management of Psoriatic D...
Psoriatic Arthritis Introduction to PsA
by phoebe-click
Key Cell Types and Activated Pathways in Psoriati...
PSA testing Common scenarios
by reagan
Asymptomatic pt. General concern. +/- . FHx. CHAPS...
Shukur W Smail /Assistant lecturer
by megan
_____________________________________________. Cli...
CCG/QEH Urology Agreements
by conchita-marotz
An update for General Practitioners. -Edgar . Pae...
Prostate Cancer Screening and Early Prostate Cancer Management
by hadly
Dr Marie-Pier St-Laurent, MD, FRCSC. Urologic-Onco...
Module 6: Prostate Cancer
by payton
Victoria . Sinibaldi. , RN, MS, CS, CANP, BC. Dani...
mCSPC Patient detailing ADT: androgen deprivation therapy; BPH: benign prostatic hyperplasia; DRE:
by olivia
Extraprostatic. . Exteneion. ; MRI: magnetic reso...
Prostate cancer: To screen or not to screen
by evans
–. To treat . or not to treat. Dr Oliver Klein â...
Emerging Treatment Strategies for Psoriatic Arthritis:
by violet
Focus on IL-23 Inhibitors. Psoriatic Arthritis. Ps...
 B. BEN SALAH, M. AMOR, M. MAATOUK, R.BEN SOUSSIA, H. KTATA, M.A. JELLALI, W. MNARI, A. ZRIG, W.
by laobeast
P. ersistent sciatic artery: report of a case and ...
Faculty Kori Dewing, ANP-BC, DNP, ARNP
by briana-ranney
Rheumatology Nurse Practitioner. University of Wa...
In biochemical recurrence after curative treatment of prost
by lindy-dunigan
1- has a detection rate of 10-20% when PSA: 1-2 n...
PSA & Prostate Cancer
by trish-goza
Dan Burke . Consultant Urological Surgeon. Uro-On...
PROSTATE CANCER
by tabitha
Investigations for Prostate cancer Presentation: ...
2SCIENTIFIC REPO 2019 915516
by cora
recurrence or systemic metastases that develop a e...
Multimodality Therapy for
by emma
High Risk Disease – . The . Surgical Perspective...
How do you know when to enter Active Surveillance and when to leave?
by bency
Kirsten Greene, MD, MS, FACS. Paul Mellon Professo...
No standardization of discharge process
by lane539
Patients were getting “lost to follow-up” (11%...
Europa Uomo Summer school 2024
by hayden600
1-6 September 2024. Erik Briers MS PHD. Europa . U...
Faculty M. Elaine Husni
by grace3
, MD, MPH. Vice Chair, Rheumatology . Director, Ar...
Target trial emulation Causal inference from observational data
by cappi
Joy Shi, PhD. Instructor of Epidemiology. CAUSAL a...
rostate cancer PC is the most common cancer and the leading cause of
by callie
279 in Mexico, PC prevalence and the consequent im...
NASPCC: ABCs of Androgen Deprivation Therapy (ADT)
by maisie
Jeanny B. Aragon-Ching, M.D., F.A.C.P.. Clinical P...
Therapies for Clinically Localized Prostate Cancer
by fauna
Background A National Institutes of Health NIH pan...
collected
by davies
Thedatawasretrospectivelyfrommedicalrecordsfor4pat...
Prostate Cancer Screening in the Post-USPSTF Era
by lindy-dunigan
Alon Z. Weizer, MD, MS. Associate Professor of Ur...
Prostate cancer isn’t colorblind
by stefany-barnette
Ruth Etzioni. Roman Gulati . Lurdes . inouE. Dham...
Gestalt
by yoshiko-marsland
T. herapy. . Interventions. Peter Schulthess. Pa...
What’s new in Urology?
by ellena-manuel
GP UPDATE. 16. th. October, 2014. Miss Janelle B...
Current Controversies in
by alida-meadow
Prostate Cancer Screening and Treatment. Mr Steph...
Load More...
